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ARTICLE
Mutations in the PKM2 exon-10 region are
associated with reduced allostery and increased
nuclear translocation
Tsan-Jan Chen 1, Hung-Jung Wang2, Jai-Shin Liu1, Hsin-Hung Cheng1, Sheng-Chieh Hsu2,3, Meng-Chen Wu1,
Chien-Hung Lu1, Yu-Fang Wu1, Jing-Wen Wu1, Ying-Yuan Liu1, Hsing-Jien Kung4,5 & Wen-Ching Wang1
PKM2 is a key metabolic enzyme central to glucose metabolism and energy expenditure.
Multiple stimuli regulate PKM2’s activity through allosteric modulation and post-translational
modifications. Furthermore, PKM2 can partner with KDM8, an oncogenic demethylase
and enter the nucleus to serve as a HIF1α co-activator. Yet, the mechanistic basis of the
exon-10 region in allosteric regulation and nuclear translocation remains unclear. Here, we
determined the crystal structures and kinetic coupling constants of exon-10 tumor-related
mutants (H391Y and R399E), showing altered structural plasticity and reduced allostery.
Immunoprecipitation analysis revealed increased interaction with KDM8 for H391Y, R399E,
and G415R. We also found a higher degree of HIF1α-mediated transactivation activity,
particularly in the presence of KDM8. Furthermore, overexpression of PKM2 mutants
significantly elevated cell growth and migration. Together, PKM2 exon-10 mutations lead
to structure-allostery alterations and increased nuclear functions mediated by KDM8 in
breast cancer cells. Targeting the PKM2-KDM8 complex may provide a potential therapeutic
intervention.
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Pyruvate kinase is the last-step enzyme in glycolysis thatcatalyzes the conversion of phosphoenolpyruvate to pyr-uvate while phosphorylation of ADP to produce ATP1.
There are four isoforms (L, R, M1, and M2) of pyruvate kinase
in mammals. The L and the R isoforms are encoded by PKLR,
while M1 and M2 isoforms are encoded by PKM, differing by a
single exon through the mutually exclusive alternative splicing
of a pair of exons (exons 9 and 10) to produce PKM1 or PKM2
(for review see ref. 2,3). PKM2 is universally expressed in
embryos4,5. In adults, PKM2 is often expressed in adipose tissue
and pancreatic islets and PKM1 in muscle and brain, while PKL
is mainly expressed in liver, kidney, and small intestine and
PKR in erythrocytes. Interestingly, PKM2 is also preferentially
expressed in regenerating liver, and in cancer4,5. Elevated
expression of PKM2 is observed in the cancerous tissues of
essentially all cancer types using the cancer genome atlas
(TCGA) datasets6, suggesting the selection of PKM2 expression
favored by cancer cells.
PKM1 and PKM2 share an overall homologous fold but differ
in a 45-amino acid stretch in the C-terminal domain of PKM2
(389‒433 residues of PKM2)7. PKM1 is constitutively stable and
active as a tetrameric form, whereas PKM2 is allosterically con-
trollable and can exist as a tetramer, dimer, or monomer in
response to various effectors. The introduction of a well-known
allosteric activator, fructose 1,6-bisphosphate (FBP), for instance,
shifts a less active T-state into a fully active R-state tetrameric
form7. Recently, metabolites, including serine (Ser), phenylala-
nine (Phe), succinylaminoimidazolecarboxamide ribose-5′-phos-
phate (SAICAR), and 3,3′,5-triiodothyroxine (T3), are being
identified as allosteric effectors of PKM28–10. Notably, the
abundance of the dimeric PKM2 in tumor cells is correlated with
increased glucose uptake and lactate production, referred to as
aerobic glycolysis or Warburg metabolism1,11,12. Switching from
PKM2 to PKM1 reverses the Warubrug metablolism in different
cancer lines and reduces the tumor growth in nude mice13.
Furthermore, potent small-molecule activators that stabilize the
tetrameric form of PKM2 interfere with anabolic metabolism and
suppress tumor growth14.
PKM2, mostly in its dimeric/monomeric state, is capable
of translocating into the nucleus via interaction with importin
α515, wherein it serves as transcriptional coactivator of HIF1α
and β-catenin16,17 or as a protein kinase phosphorylating
nuclear proteins histone H3 and Stat3, further facilitating cell
proliferation15,18–20. At the same time, the cytosolic pyruvate
kinase activity is reduced, leading to the accumulation of glyco-
lysis intermediates, fueling the biosynthesis of nucleotides,
amino acids and lipids; this also additionally reduces the pyruvate
kinase activity of PKM2. We have previously shown that PKM2
makes partnership with the oncogenic histone demethylase
KDM8, which also promotes PKM2 nuclear translocation21.
KDM8, a crucial factor for embryogenesis22, oncogenesis22,23,
and stem-cell renewal24, is overexpressed and amplified in various
tumor tissues23,25,26. It regulates the cell cycle by upregulating the
expression of cyclin A23,27,28, and down-modulating that of p53
and p2122. Because KDM8 is expressed in virtually all tumor
cells21, its role as a nuclear translocator of PKM2 in the context of
oncogenesis deserves some attention.
The tetramer-dimer-monomer ratio of PKM2 is also regulated
by post-translational modifications (PTMs). For instance, Lys433
of PKM2 is acetylated in the presence of mitogenic or oncogenic
stimuli, Tyr105 is phosphorylated by growth factor signals, and
Lys305 is acetylated by high glucose, shifting to the less active
dimeric form of the enzyme29–32. However, the mechanistic basis
of the exon-10 region in structure flexibility, allosteric regulation
and the nuclear translocation in the context of KDM8 remains to
be elucidated.
In this investigation, three tumor-related mutants, H391Y,
R399E, and G415R18,33–35, were chosen to characterize the
allostery and nuclear translocation activity and its relationship
with KDM8. H391Y, a variant from a Bloom syndrome patient,
exhibits a cross-monomer interaction with wild-type PKM2 for
affecting PKM2 oligomerization and cell growth34. Bloom syn-
drome patients exhibiting BLM deficiency are characterized by a
significantly increased incidence of all types of cancer at an early
age36. R399E, an engineered, oncogenic mutant at the C–C
interface region, substantially promoted tumor growth in a nude
mouse model18. G415R, whose residue is situated at the
dimer–dimer interface, was identified from a patient with kidney
cancer35. Here, we demonstrated that these variants displayed
considerably reduced allosteric regulation. We determined the
crystal structures of H391Y and R399E, revealing mutation-
driven conformational changes at the C–C interface, which are
responsible for the substantial forfeiture of the allosteric con-
formational switch. In addition, compared with the wild-type
enzyme, R399E, H391Y, and G415R mutants favorably interacted
with KDM8 and exhibited enhanced nuclear translocation and
HIF1α-mediated transactivation activity. These effects are even
more pronounced in the presence of KDM8. Finally, we
demonstrated that PKM2 mutants dramatically promoted tumor
cell growth and migration.
Results
Clinical relevance of PKM2 and KDM8 in tumors. Data for
immunohistochemical (IHC) staining from The Human Protein
Atlas project (http://www.proteinatlas.org/) revealed that a
majority of tumor tissues overexpress PKM2. In parallel, PKM2
was frequently overexpressed in tumor sections (the Oncomi-
neTM database; http://www.oncomine.org/), thus indicating its
positive contribution to tumor growth. In addition, data from
The Human Protein Atlas revealed that most malignant tumors
also exhibited KDM8-positive IHC signals. Hsia et al. reported
that KDM8 was overexpressed in multiple types of tumors,
including breast, uterine, and liver tumors23. Notably, results of
an analysis of a large collection of breast cancer tissues (n= 2509)
from the Molecular Taxonomy of Breast Cancer International
Consortium (METABRIC) database revealed that both PKM2
and KDM8 are significantly overexpressed in breast cancer
samples compared with the normal control samples (p < 0.001)37
(Fig. 1a). Furthermore, mutual exclusivity and co-occurrence
analyses of the METABRIC data set with mRNA expression
z-scores ± 2.0 revealed that the co-occurrence of both PKM2 and
KDM8 was statistically significant (p= 0.015)25,26. Similar
results were also obtained for The Cancer Genome Atlas (TCGA,
http://www.cbioportal.org/) kidney renal clear cell carcinoma
(n= 538, p= 0.033). These results suggest co-occurring differ-
ential expression of PKM2 and KDM8 in these cancers.
We next utilized an interactome-based tool PRISURV to
characterize the association of PKM2 and KDM8 expression
levels with clinical outcomes38. PRISURV analysis revealed a
large number of PKM2 interaction partners (n= 1081) but no
known partners for KDM8. Further characterization indicated
that the probed PKM2 interactomes were significantly associated
with clinical outcomes in 12 clinical cancer data sets (Fig. 1b;
Table 1). Of these, 11 had negative survival outcomes, including
lung cancer (4), breast cancer (2), liposarcoma (1), prostate
cancer (1), leukemia (1), colon cancer (1), and glioma (1), which
is consistent with the positive contribution of PKM2 to cancer
metabolism.
PKM2 exon-10 variants exhibit a reduced allosteric effect. To
investigate the mechanistic basis of the exon-10 region involved
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in the allosteric effect of PKM2, we used tumor-related variants
near the C–C interface: an oncogenic mutant R399E that pro-
motes tumor growth in a mouse model18, a natural variant
H391Y from Bloom syndrome patients with a risk of cancer33,34,
and G415R found in tumor samples35. The purified G415R
expressed in Escherichia coli, however, was quite unstable and
exhibited essentially no detectable pyruvate kinase activity. The
subsequent biochemical analyses were thus done for H391Y and
R399E.
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Fig. 1 Clinical relevance of PKM2 and KDM8 in cancers. a PKM2 and KDM8 were overexpressed using METABRIC (the Molecular Taxonomy of Breast
Cancer International Consortium) database (***p < 0.0001, two-tailed t-test). The source data is available in Supplementary Data 1. b Negative survival
outcomes in two data sets from Table 1. N, normal. G1 to G3, grade 1 to grade 3
Table 1 PRISURV analysis of PKM2 interactomes
GEO dataset Cancer type GENE (Probe ID) p-value Effect sign
GSE31210 Lung cancer 201251_AT 9.7e-05 Negative
GSE30929 Liposarcoma 201251_AT 0.000342 Negative
GSE11969 Lung cancer 3739 0.00194 Negative
GSE36471 Lung cancer 24498 0.00236 Negative
GSE13507 Bladder cancer ILMN_1663122 0.00266 Positive
GSE16560 Prostate cancer DAP3_2320 0.00488 Negative
GSE22762 Chronic lymphocytic leukemia 201251_AT 0.0126 Negative
GSE17536 Colon cancer 201251_AT 0.0195 Negative
GSE4271 High-grade glioma 201251_AT 0.0241 Negative
GSE22220 Breast cancer 2030537 0.0338 Negative
GSE24450 Breast cancer ILMN_1672650 0.0428 Negative
GSE4573 Lung cancer 201251_AT 0.0448 Negative
Table 2 Allosteric coupling constants of PKM2 variants
Qaxa FBP Ser Phe
Wild-type 11.70 ± 2.62 1.22 ± 0.10 0.09 ± 0.01
H391Y 3.56 ± 0.22 1.35 ± 0.07 0.15 ± 0.01
R399E 4.10 ± 0.62 1.18 ± 0.07 0.22 ± 0.02
aCoupling constant (Qax) is derived from the equation Ka ¼ K0ia K0ix þ PEP½ 
 
= K0ix þ Qax PEP½ 
  
.
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The apo-form H391Y and R399E had a slightly higher relative
activity (163 and 137%) as compared with wild-type PKM2. We
evaluated allosteric properties for H391Y and R399E by the
linked-function analysis developed by the Reinhart’s laboratory39.
The effect of an effector (FBP, Ser, or Phe) on the binding of
phosphoenolpyruvate (PEP) for wild-type PKM2 was assessed by
the plot of Ka for PEP as a function of a effector concentration.
The derived values of coupling constant (Qax) based on the
linked-function equation are given in Table 2. As shown in Fig. 2,
increasing concentrations of the activator FBP led to an evidently
enhanced degree of the PEP binding affinity for wild-type PKM2,
yielding a large value of Qax= 11.70. For Ser, there was a
relatively horizontal profile and Qax= 1.22, suggesting that FBP is
a much potent allosteric activator for the PEP binding affinity as
compared with Ser. For the inhibitor Phe that binds at the same
effector site of Ser, the magnitude of the inhibition was quite
strong, generating a noticeably inverse trend and Qax < 1(0.09).
We next evaluated the allosteric properties per PKM2 variant.
H391Y and R399E exhibited a reduced level of FBP activation
profile (Fig. 2) and decreased values of Qax (3.56 and 4.10)
(Table 2). For Ser, these variants displayed similarly horizontal
patterns and comparable values of Qax, indicating that Ser had a
limited effect on the PEP binding affinity. By contrast, the
inhibitor Phe inversely impacted the PEP binding affinity for
H391Y and R399E (Qax: 0.15, 0.22), albeit with a much lower
effect as compared with wild-type PKM2. The apo-form H391Y
and R399E displayed a slightly higher PEP binding affinity while
considerably weaker coupling between FBP and PEP binding as
compared with wild-type PKM2, indicating that binding affinity
and allosteric effectiveness can be independent and uncorrelated
to one another. A similar allosteric behavior is also reported for
phosphofructokinase40. Together, our results suggest that FBP
and Phe were prominent allosteric effectors and H391Y and
R399E dramatically lost the allosteric properties.
Structures of H391Y and R399E demonstrate altered con-
former. The crystal structures of H391Y·Ser·FBP (R= 14.4%,
Rfree= 21.7%) and R399E·Ser·FBP (R= 18.0%, Rfree= 21.8%)
were determined through the molecular replacement method
(Table 3). Figure 3a shows a clear electron density map of the
substituted side chain for H391Y or R399E. The model consists of
four subunits, and each monomer of H391Y and R399E displayed
an overall homologous fold similar to that of the wild-type
(Fig. 3b); each monomer (531 amino acids) comprised N region
(1‒43), A domain (44‒116 and 219‒389), B domain (117‒218)
and C domain (390‒531)7. The active site is situated at A
domain in close proximity to B domain, and the FBP-binding
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Fig. 2 The coupling effect between the PEP binding affinity and an allosteric effector by the linked-function analysis. The profile of Ka values for PEP of
PKM2 (wild-type, H391Y, or R399E) vs. an effector (FBP, Ser, or Phe) was measured. Data from three independent experiments are presented as mean ±
SD. WT, wild-type
Table 3 Crystallographic statistics of PKM2 variants
PKM2 H391Y(Ser) R399E(Ser)
PDB 4YJ5 5X0I
Data collection
Space group P21 P212121
Unit cell
a (Å) 73.22 116.60
b (Å) 140.89 137.88
c (Å) 108.72 149.71
Resolution (Å) 20.00–2.41 30.00–2.64
Unique reflections 83766 72242
Completeness (%)a 99.9 (99.9) 99.9 (100)
Average I/σ (I)a 17.0 (4.2) 16.6 (4.0)
Redundancya 4.3 (4.4) 4.8 (5.0)
Rmerge(%)a,b 7.8 (39.1) 9.3 (49.7)
Refinement
R value (%)c 14.4 18.0
Rfree value (%)d 21.7 21.8
R.m.s.d. bond lengths (Å)f 0.015 0.016
R.m.s.d. bond angles (°)f 1.906 1.477
Ligands FBP/Ser FBP/Ser
aValues in parentheses refer to statistics in the highest-resolution shell
bRmerge= Σ|I − <I>|/Σ(I)
cR= Σ|Fobs-Fcalc|∕ΣFobs, where Fobs and Fcalc are the observed and calculated structure-factor
amplitudes, respectively
dRfree was computed using 5% of the data assigned randomly
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(431‒437, 482, 489, 513‒522) and Ser-binding (43‒46, 70, 106,
464‒471) sites were situated in the C domain. Notably, an
exclusive exon-10 region (378‒434) of PKM2 resides was
observed near the intersubunit interface (A–A and C–C) (Sup-
plementary Fig. 1). Table 3 summarizes the crystallographic sta-
tistics of PKM2 variants.
The replacement of H391 with Y391 introduced a strong
hydrogen bond contact between the hydroxyl group of Y391
and carboxyl group of E386 (3.0 Å), which strengthened the
connection of the two helices (residues 371−388 and 391−401)
near the C–C interface (Fig. 3c). The wild-type exhibited strong
salt-bridge intersubunit interactions among R399, E396, and
E418 at the C–C interface. However, substitution by E399
essentially forfeits these contacts because of an anionic carboxyl
moiety, even in the presence of FBP, and thus a conformer that
lost allosteric regulation (Fig. 3d). We could not obtain crystals
of G415R given its instability. The structural analysis of
G415 shows that G415 is situated at the middle of a long helix
(residues 407−423) at the C–C interface. Replacement with
arginine introduced a long, guanidine side chain at this position,
which is presumed to perturb the helical conformation and
tetrameric assembly. Collectively, these results suggest that the
C–C interface variants exhibited altered structural elements
that interfere with the conformational transformation into an
active form and allostery.
PKM2 exon-10 variants display increased interaction with
KDM8. KDM8 makes direct partnership with PKM2 to promote
its nuclear translocation and the subsequent transactivation
event21. Since PKM2 interacts with KDM8 through its C-terminal
domain21, we asked whether PKM2 exon-10 variants with altered
C–C interface conformation affected the binding affinity with
KDM8. We used co-IP experiment of lysates from MCF7 cells co-
transfected with HA-tagged PKM2 (wild-type, R399E, H391Y, or
G415R) and Flag-tagged KDM8. Each of PKM2s was immuno-
precipitated using anti-HA antibodies, followed by Western
blotting analysis. Figure 4a shows that all three exon-10 variants
(R399E, H391Y, and G415R) exhibited higher affinity to KDM8
as compared with wild-type PKM2. The full-sized blot images are
shown in Supplementary Fig. 2. A reciprocal immunoprecipita-
tion (IP) assay using anti-Flag antibody to precipitate KDM8 also
revealed stronger interaction with the PKM2 variants (Fig. 4b).
In addition, the association of PKM2 mutants with endogenous
KDM8 in MCF7 cells was studied. IP analysis using anti-KDM8
revealed that each mutant exhibited a higher degree of interaction
with endogenous KDM8 than did wild-type PKM2 (Fig. 4c).
We next evaluated the KDM8-PKM2 interaction using cell-free
pull-down assays with purified His-tagged PKM2 and GST-
KDM8. Figure 4d shows that GST-KDM8 had stronger interac-
tion with R399E and H391Y as compared with wild-type PKM2.
Size-exclusion chromatographic analysis of purified recombinant
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Fig. 3 Structural analysis of PKM2 wild-type and variants. a The 2Fo-Fc electron density map of H391Y and R399E. The map is contoured at the 1.1-σ level.
b Superposition between wild-type (R-state, green), H391Y (cyan), and R399E (gray) monomers. Mutated residues are shown as heavy sticks. FBP, serine,
and oxalate are drawn as ball-and-stick models. The carbon, oxygen, and nitrogen atoms are colored yellow, red, and blue, respectively. c Structural
analysis of wild-type PKM2 and H391Y shows that H391Y possesses a strong hydrogen bond contact between Y391 and E386. The right panel is a zoomed
region of 30 degree rotation clockwise of the left panel. d Comparison between wild-type PKM2 and R399E shows that R399E fails to form a salt-bridge
network among R399, E396, and E418 at the C−C interface. The right panel is a zoomed region of the left panel. Residues (E386, H391, Y391, R399, E399,
E396, and E418) are shown as sticks. The oxygen and nitrogen atoms are colored red and blue, respectively. wild-type (PDB: 3SRD; green); H391Y (PDB:
4YJ5, this study; cyan); and R399E (PDB: 5X0I, this study; gray)
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proteins demonstrated that in the presence of KDM8, a higher
proportion of PKM2 variants (R399E and H391Y) shifted to the
position (12.5−13-mL fractions) with molecular masses corre-
sponding to a dimeric (PKM2)2 or PKM2–KDM8 than did wild-
type PKM2 (Supplementary Fig. 3). Thus, those exon-10 variants
not only caused structural alterations near the C–C interface and
lessened the allosteric regulation, but also interacted favorably
with KDM8.
PKM2 variants promote cell malignancy together with KDM8.
PKM2, primarily in the dimeric form, translocates into the
nucleus and serves as a coactivator for transcriptional factors,
including HIF1α, Stat3, β-catenin, and Oct-441. We have pre-
viously demonstrated that KDM8 promotes the nuclear translo-
cation of PKM2. Accordingly, we determined whether the exon-
10 point-mutation variants altered the degree of KDM8-mediated
translocation. We utilized confocal microscopic analysis to
visualize the distribution of PKM2 and KDM8 in MCF7 cells
transfected with PKM2 alone or PKM2 plus KDM8 (Supple-
mentary Fig. 4). Cell numbers of at least 50 per assay were
calculated to determine the level of nuclear translocation. Over-
expression of mutant PKM2 alone led to an increased proportion
of cells harboring nuclear PKM2 as compared with that of wild-
type PKM2; R399E and G415R exhibited statistical significance
(Fig. 5a, b). Remarkably, overexpression of KDM8 and each
variant showed a significantly increased proportion of cells with
nuclear PKM2 signal compared with that of PKM2 alone. There
was also a slightly increased fraction of nuclear-PKM2 cells for
cells co-transfected with KDM8 and wild-type PKM2 (Fig. 5b).
We then surveyed the signal of nuclear PKM2 in those cells. Of
note, the intensity of nuclear PKM2 in cells showing Flag-KDM8
signal (n= 7) was significantly higher with that in cells without
Flag-KDM8 signal (n= 7) (Supplementary Fig. 5).
We next asked whether the depletion of KDM8 had an inverse
effect by using control (LKO) and KDM8-depleted (shKDM8)
cells21. Analysis of nuclear and cytosolic fractions from lysates of
LKO cells transfected with HA-PKM2 revealed that overexpres-
sion of each PKM2 mutant had a slightly higher level of nuclear
PKM2 than did that of wild-type PKM2 (Fig. 5c). For shKDM8
cells, overexpression of wild-type and mutants had essentially no
nuclear PKM2 signal detected, suggesting that KDM8 accelerated
PKM2’s nuclear translocation.
To substantiate this notion, we measured the HIF-1 transacti-
vation activity using a HIF1α-based reporter activity assay21.
MCF7 cells were co-transfected with pHRE-FLuc, an internal
control vector, and the empty vector or PKM2 (wild-type, R399E,
H391Y, or G415R) in the absence or presence of KDM8 vectors.
Figure 5d shows that cells co-expressing PKM2 and KDM8 had a
significantly higher activity than did those expressing PKM2
alone. Furthermore, compared with wild-type PKM2 alone, a
higher mean transactivation activity per variant was also
observed.
We then evaluated whether overexpression of PKM2 mutant
can promote cancer progression. Figure 6a shows that over-
expression of each mutant (R399E, H391Y, and G415R) in MCF7
cells had a significantly higher growth rate as compared with
that of wild-type PKM2 over a five-day period. Additionally,
compared with wild-type, each variant exhibited a significantly
elevated level of migration (Fig. 6b, c). Together, these results
suggest that the allostery-insensitive PKM2 variants confer
increased regulation by KDM8 and promote aggressive cancer
progression.
Discussion
Taken together, we provided a key mechanistic basis of trans-
formation of PKM2 into a signaling molecule through the
Input
WB: HA
(PKM2)
IP: HA
W
T
R
39
9E
H
39
1Y
G
41
5R
WB: Flag
(KDM8)
WB: HA
(PKM2)
WB: Flag
(KDM8)
– 55
– 70
– 55
– 70
kD
a
Input
WB: HA
(PKM2)
IP: Flag WB: Flag
(KDM8)
WB: HA
(PKM2)
WB: Flag
(KDM8)
W
T
R
39
9E
H
39
1Y
G
41
5R
– 70
– 55
– 70
– 55
kD
b
HA-PKM2 vectors
Input
WB: HA
(PKM2)IP: KDM8
WB: KDM8
(endo.)
W
T
R
39
9E
H
39
1Y
G
41
5R
EV Ig
G
WB: HA
(PKM2)
WB: KDM8
(endo.)
– 55
– 70
kD
– 55
– 70
c
G
ST
-p
ul
l d
ow
n
WB: His
(PKM2)
CBB:
GST-KDM8
GST
– 70
– 55
kD
– 70
– 100
– 40
– 25
W
T
R
39
9E
H
39
1Y
W
T
R
39
9E
H
39
1Y
GST GST-KDM8d
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structural changes near the C–C interface and hence allosteric
resistance by characterization of PKM2-specific exon-10 variants
(H391Y, R399E, and G415R). The coupling-function analysis
revealed that wild-type PKM2 displayed a strong coupling effect
between the PEP binding affinity and FBP. In contrast, there was
a considerably weaker coupling effect for H391Y and R399E. A
similarly inverse coupling pattern was seen for the other effector
Phe. From the structural point of view, the large coupling effect
between FBP and the PEP binding affinity for wild-type PKM2
is in good agreement with a large T-to-R conformational change
induced by FBP so as to generate a much tighter substrate-
binding environment for catalysis7.
PKM2 consists of the other Phe/Ser allosteric site distinct from
the FBP site10,42. Of note, the PKM2-Phe complex structure is
present as a T form (PDB: 4FXJ), while the Ser-liganded one
(PDB: 4B2D) is an R form10,42. Superposition of PKM2-Phe and
PKM2-Ser complexes reveals a larger pocket for the Phe-liganded
complex. Since Phe possesses a bulky hydrophobic side chain, it is
likely that binding of Phe to this site may induce an R-to-T
conformational change, leading to an inverse coupling trend.
On the other hand, Ser has a much smaller side chain and can
fit quite well into this smaller pocket seen in the Ser-liganded
structure. This might explain why Ser had a limited coupling
effect.
The structures of H391Y and R399E clearly show an altered
conformer at the C–C interface. H391Y is a considerably rigid
conformer because of an additional strong hydorgen bond
between two nearby helices, which is likely to greatly reduce the
T-to-R conformational change and the allosteric regulation.
R399E shows a diminished salt-bridge network near the C–C
interface. As such, R399E exhibits an FBP-resistant allosteric
activation as seen in the coupling-function analysis. Despite no
G415R structure, the substitution of G415 with Arg situated in
the middle of an intersubunit helix (405–423) may destabilize the
dimer–dimer contacts, and this notion is supported by the
observation of prompt aggregation after purification. Thus, those
variants demonstrate altered conformation near the C–C inter-
face and hence resistance to allosteric regulation.
PTM provides an alternative strategy to interefere with allos-
teric regulation of PKM2. For instance, an acetylated-K433 PKM2
or its acetylated mimic K433Q confers nonresponsiveness to FBP
and exhibits a higher degree of nuclear transformation29. Phos-
phorylation of Y105 also resists to FBP-mediated activation43.
Thus, those PKM2s with acquired resistant allostery, either from
mutations or PTMs, are prone to transforming into a signaling
molecule. Interestingly, the C-terminal segment consists of R445,
R447, and R455 from PKM2 but not from PKM1 can be
methylated by CARM1, which activates aerobic glycolysis but
suppresses oxidative phosphorylation through regulating the
expression and interaction with inositol 1,4,5-triphosphate
receptors44. This finding reveals an additional layer of regulation
for dimeric PKM2 that possibly has an exposed C-terminal region
as opposed to PKM1. Thus, an endured or even a persistent
dimeric/monomeric form of PKM2 not only curbs its pyruvate
kinase activity but also is inclined to exposing the nuclear loca-
lization signal region45, a regulatory region44, or perhaps a
peptide-interaction region near the C–C interface region given
the lack of tetrameric assembly. This allows PKM2 interact with
importin α515 or a nuclear partner KDM821 to facilitate nuclear
translocation, or a subsequent methylation of the C-terminal
segment to promote aerobic glycolysis44. Together, these results
highlight the importance of endurance of a dimeric/monomeric
PKM2 status through indolent allostery in cancer metabolism.
We also demonstrated an accelerated increase in nuclear
translocation and transactivation activity in the presence of
KDM8, an oncogenic histone demethylase23. We have previously
reported that KDM8 is frequently overexpressed in several types
of tumors; it heterodimerizes with PKM2, facilitates the nuclear
translocation of wild-type, and therefore promotes HIF1α-
mediated transactivation21. Here, the mutants displayed a
higher level of nuclear translocation and HIF1α-mediated trans-
activation activity. It is noted that the two different approaches
(confocal microscopic analysis and HRE promoter activity ana-
lysis) utilized here had a slight discrepancy in the case of over-
expression of mutant PKM2 alone. Our speculation is that the
endogenous amounts of KDM8 are not sufficiently enough to
lead to a substantial degree of PKM2 nuclear translocation which
can be evidently detected by confocal microscopic analysis. On
the other hand, the HRE promoter activity assay that employs the
reporter plasmid carrying 3 HRE repeats fused to firefly luciferase
is much more sensitive, hence an increased level of HRE signal.
We have previously mapped that the most critical KDM8 inter-
action region of PKM2 is situated at the C-terminal part (residues
366−476)21. Docking analysis also reveals that a monomeric
PKM2 contacts with KDM8 through its C-terminal domain
(Supplementary Fig. 6a). This interaction appears to disrupt the
tetrameric form of PKM2, in favor of the “nuclear translocatable”
dimer/monomer form (Supplementary Fig. 5) and facilitate
hypoxia-inducible HIF1α-mediated transactivation. Our previous
work also indicated that KDM8 catalytic mutant was able to
enhance HIF1α-mediated transactivation via PKM2 transloca-
tion21, suggesting its activity is not required for this process.
Interestingly, the analyses of TCGA and ICGC databases reveal
numerous mutations clustered at the exon-10 region, in addition
to G415R (V399M, R400H, E410K, A412V, V417L, A413V,
V414M, and A427V) (Supplementary Fig. 6b)25,26, reflecting a
potential selection advantage. It is thus likely that those exon-10
variants including H391Y, R399E, and G415R that bear the
reduced-allostery trait confer the major proliferative advantage
even in the absence of KDM8.
Based on the results of this study, we propose that the selection
of allostery-resistant mutants at exon 10 provides an alternative
pathway to enhance its non-metabolic function for a growth
advantage to tumor cells. This reveals a new mutation-driven
oncogenic feature of PKM2 mutations, in addition to non-
enzymatically functional proteins resulting from truncated/fra-
meshift mutations and missense mutations of PKM2, predicted
to lower or reduce enzymatic activity35. These findings collec-
tively strengthen the notion that PKM2 is a key isoform in cancer
metabolism.
Previously, small-molecule PKM2 activators crosslinking the
A–A interface to attain a constitutively active tetramer have been
developed to suppress aerobic glycolysis to reduce the tumor
growth14. Kung et al. reports that pharmacological activation of
PKM2 using small-molecule activators induces serine auxotrophy
for continued cell proliferation in A54946. This implies that
PKM2 with tunable kinase activity regulates the metabolic state so
as to manage the requirements of multiplying tumor cells and
that cells persistently carrying high-activity PKM2 form might
reroute its metabolism for sustained tumor growth. Instead, tar-
geting the PKM2–KDM8 partnership in tumors carrying abun-
dant expression of PKM2 and KDM8 represents a potential new
intervention strategy. We have previously demonstrated that
the knockdown of KDM8 compromised the growth of cancer
cells21–23. Interestingly, a recent study reports that nuclear PKM2
can be substantially retained in the presence of the polymer of
ADP-ribose (PAR) in EGFR-mutant cancers47. The depletion of
PAR suppressed PKM2 nuclear localization and the cell growth of
EGFR-mutant cancers47. By the use of the PC3 cell model,
blocking the nuclear translocation of PKM2 using DASA-58
or metformin significantly impaired metastatic propagation in
SCID mice9. These results suggest a new avenue for cancer
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interventions through the targeting of nuclear PKM2 or the
PKM2–KDM8 partnership.
In sum, we demonstrate that tumor-related exon-10 mutations
in PKM2 conferred altered conformation near the C–C interface
region, a substantial decrease of allosteric regulation, and
increased interaction with KDM8, facilitating nuclear transloca-
tion and transactivation (Fig. 7). This is particularly pronounced
in the presence of KDM8, an oncogenic partner highly over-
expressed in breast tumors. These results add a mutation-driven
strategy to transform PKM2 into a signaling molecule, which can
rewire cell metabolism to meet the special metabolic demands of
proliferating tumor cells in appropriate context. Targeting the
PKM2-KDM8 complex may provide a potential therapeutic
intervention of PKM2-associated tumors.
Methods
Plasmid construction. PKM2 full-length cDNA was amplified by PCR using DNA
polymerase (SMOBIO Technology, Inc.) and dNTP (Genedirex, Las Vegas City,
NV, USA) and ligated to pET28a (Novagen) vector for E. coli expression. All PKM2
mutants were generated by site-directed mutagenesis method. For eukaryotic cell
expression, PKM2 wild type and mutant cDNAs were inserted into pcDNA3.1
vector. The primer sequences used for PCR amplification are shown in Supple-
mentary Table 1. All sequences were verified by DNA sequencing (Supplementary
Data 2).
Expression and purification of PKM2. Protein expression of E. coli BL21 (DE3)
carrying desired PKM2 wild type/mutant plasmids were induced by 1.0 mM IPTG
(isopropyl-β-D-thiogalactopyranoside) under 16 °C incubation. Cells were har-
vested and homogenized by sonication. After centrifugation (10,000 × g at 4 °C for
20 min), the recombinant protein was purified from crude extract by using cobalt-
chelated TALON Metal Affinity Resin (Clontech) under the manufacturer’s
instruction. Eluted protein was concentrated and dialyzed into Tris buffer (40 mM
Tris, 100 mM KCl, pH 7.5) using a Amicon Ultra-15 30,000M.W. tube (Millipore).
Protein purity was checked by SDS-PAGE followed by Coomassie brilliant blue
staining.
Measurement of PKM2 activity and allostery. The in vitro PKM2 pyruvate
kinase activity was determined by measuring OD340 of lactate dehydrogenase-
coupled reaction. A steady-state kinetic reaction was carried out in 50 mM Tris
(pH 7.5), 100 mM KCl, 5 mMMgCl2, 1 mM ADP, 0.4 mM NADH, 2 U LDH, 25 ng
PKM2 and the [PEP] in the range of 0.06–8 mM in total volume of 200 μL at 37 °C.
Kinetic parameters were obtained using nonlinear regression fitting to the
Michaelis–Menten equation; the errors in the parameters were less than 5%.
Coupling constant (Qax) which describes the effect of an effector (FBP, Ser, and
Phe) on the binding of PEP is derived from the linked-function analysis
Ka ¼ K0ia K0ix þ ½PEP
 
=K0ix þ Qax PEP½ 
 
39, where Ka is dissociation constant
defined as the concentration of substrate that yields a rate equal to one-half of the
Vmax, K0ia is the dissociation constant for PEP in the absence of an allosteric
effector, and K0ix is the dissociation constant for an allosteric effector in the absence
of PEP. The kinetics data were collected by using CLARIOstar V5.01 R4 software.
Coupling constants were analyzed by using GraphPad Prism 6.01.
Size-exclusion chromatography. Size-exclusion chromatography was carried
out using ÄKTA FPLC system. PKM2 protein was aliquot to 100 μL at the
concentration of 2.5 mg/mL in PBS in the absence or presence of appropriate
amounts per allosteric effector and run onto the Bio-Rad ENrich™ SEC 650 column
equilibrated with PBS at the flow rate of 1 mL/min. The elution process was
monitored by OD280, and eluted protein was collected with 0.5 mL fraction size.
Protein crystallization. Initial crystallization screening was carried out by using
the Oryx8 robot (Douglas Instruments, UK). Subsequent crystal optimization was
performed by mixing equal volumes of a protein sample (8.0 mg/mL PKM2) and
the reservoir solution (0.1 M Tris, pH 7.5, 0.2 M NaCl, 14% w/v polyethylene glycol
3350) using hanging drop vapor diffusion method at 4 °C.
X-ray data collection and structure refinement. X-ray diffraction data of
H391Y·Ser·FBP and R399E·Ser·FBP structures were collected at National Syn-
chrotron Radiation Research Center (NSRRC, Hsinchu, Taiwan) using ADSC
Quantum-315r CCD area detector. H391Y·Ser·FBP and R399E·Ser·FBP crystals
were freshly mounted at BL13B1 and BL13C1 beamlines, respectively. All dataset
integration and scaling were calculated using HKL-2000. Data collection statistics
are shown in Table 3.
The PKM2 structure models were constructed by using Molrep program in
CCP4 interface (version 2.2.1). The starting model for molecular replacement was
wild type PKM2 structure from Protein Data Bank (PDB code: 4B2D). Structure
refinement was done by using the REFMAC5 program in CCP4 interface. Manual
refinement of the structures was done by using COOT (version 0.7.2) program.
Structural modeling of the PKM2-KDM8 complex. The PKM2–KDM8 complex
model was generated by the ZDOCK module of the Discovery Studio 2017 client
(Accelrys Inc., USA). The input PKM2 and KDM8 coordinates were extracted from
the structures of PKM2 (PDB code: 3SRD)10 and KDM8 (PDB code: 4GJY)48,
respectively. The identified interaction regions in PKM2 and KDM821 were
selected as the binding sites. All generated poses were ranked according to the
spatial proximity and the energy by the ZDock and ZRank scoring functions. The
top-ranking poses were refined and optimized by refined docked proteins
(RDOCK).
GST pull down assay. His-tagged PKM2 (2 μM) and GST-tagged KDM8 (1 μM)
or GST alone (1 μM) was incubated with pre-equilibrated GST beads (Glutathione
Sepharose, GE) in Tris buffer [40 mM Tris, 100 mM NaCl, 0.5% Nonidet P-40, pH
8.0, and 1× protease inhibitor cocktail (Thermo)] for 2 h under 4 °C with agitation.
The GST beads were centrifuged down and washed with the Tris buffer for three
times. The samples were subject to 10% SDS-PAGE separation, followed by
Coomassie brilliant blue staining and Western blotting analysis. Anti-His antibody
(1:2000, CusAb) was used for the immunoblotting.
Co-immunoprecipitation assay. MCF7 cells were purchased from the Bioresource
Collection and Research Center of Food Industry Research and Development
Institute, Taiwan. Cells harvested from culture dishes were lysed in IP lysis buffer
Fully active
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Low  allostery
PKM2
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variants
Partially active
KDM8 FBP
Nucleus
Substrate
Fig. 7 The proposed model that depicts the mechanistic basis of PKM2 exon-10 mutations in allosteric regulation and KDM8-mediated nuclear
translocation. WT, wild-type
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[50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% Nonidet P-40, 5% glycerol, 1 mM
EDTA, and 1× protease inhibitor cocktail (Thermo)], followed by centrifugation
(16,000 × g, 4 °C, 10 min) to remove insoluble debris. The lysates were incubated
with 1 μg anti-HA or anti-Flag antibodies (Cell Signaling) and 10 μL of protein A/G
magnetic beads (Invitrogen) at 4 °C overnight with agitation. Homemade rabbit
anti-KDM8 antibody was used to precipitate endogenous KDM8. The beads were
washed with IP lysis buffer for three times and subject to separation by 10% SDS-
PAGE, followed by Western blotting analysis using the antibodies as indicated.
Confocal microscopic analysis. MCF7 cells were fixed with 3.7% paraformalde-
hyde for 20 min and penetrated by treatment with blocking buffer (2.5% fetal
bovine serum in PBS) containing 0.1% of Triton X-100 for 30 min. HA-PKM2 and
Flag-KDM8 were marked with rabbit anti-HA-tag (1:500, SignalChem) and mouse
anti-Flag-tag (1:500, Sigma-Aldrich), respectively. Cell nuclei were stained with
Hoechst 33342. Alexa-488–conjugated anti-rabbit (1:500) and Cy5-conjugated
anti-mouse (1:500) IgGs were used as secondary antibodies (Jackson ImmunoR-
esearch Laboratories). Cells were examined in a Zeiss LSM 780 laser-scanning
microscope with a Plan-Apochromat 20×/0.8 M27 objective. Images were analyzed
using the LSM 780 META ZEN 2011 software package (Carl Zeiss). Mean fluor-
escent intensity was analyzed by using imageJ software. Statistical analysis was
done by using Microsoft Excel 2016.
Lentivirus production. HEK293T cells were seeded onto 10-cm culture dishes. The
cells were transfected one day later by using LipofectamineTM 2000 (invitrogen)
with lentiviral transducing vector encoding pLKO or shKDM8 and packaging
vectors. After 72 h, virus particles were harvested from the medium and filtered
through a 0.45-mm syringe-driven filter (Millipore).
Subcellular fractionation. MCF7 cells were scrapped from tissue culture plates
and lysed in hypotonic buffer (20 mM Tris, pH 7.4, 10 mM NaCl, 3 mMMgCl2) for
15 min on ice. Mild detergent (Nonidet P-40) was added to a final concentration of
0.5%. The nuclear fraction was precipitated by centrifugation at 800 × g for 10 min
at 4 °C. The supernatant was collected as the cytosolic fraction, and the pellet was
further lysed in complete lysis buffer (40 mM Tris, pH 7.4, 100 mM NaCl, 0.5%
Nonidet P-40) to serve as the nuclear fraction.
Luciferase activity assay. Cells were transfected with pHRE-Firefly luciferase
reporter, internal control reporter pTK (Thymidine kinase)-Renilla luciferase
(Promega), pcDNA3.1-HA control, per PKM2 vector (pcDNA3.1-HA-PKM2,
pcDNA3.1-HA-R399E, pcDNA3.1-HA-H391Y, or pcDNA3.1-HA-G415R) or plus
pcDNA3.1-Flag-KDM8 in 48-well plates. Firefly and Renilla luciferase activities
were measured by using the Dual- Luciferase Assay System (Promega) following
the manufacturer’s instruction.
Cell proliferation assay. MCF7 cells were seeded in six-well plates (3 × 105 cells
per well) and transfected with each PKM2 plasmid indicated. The cell number was
counted each day in a five-day interval. Data represent the mean ± SD of three
independent replicates.
In vitro migration assay. For the migration/chemotaxis assays, we used cell
migration kit (CytoSelect, CBA-100). In brief, cells were transfected with the
indicated vectors and recovered for 24 h. Cells (2 × 105) were suspended in serum-
free medium and seeded on top of the membrane. Serum-containing medium was
placed at the bottom and cells that had migrated to the lower surface of the
polycarbonate membrane were stained and counted after 16 h. A colorimetric
approach by measuring OD 560 nm was used for quantification.
Antibodies. Anti-HA antibody used in the immunoprecipitation experiment was
purchased from Cell Signaling (catalog number: C29F4; lot number: 8). Anti-HA
antibody used in the confocal microscopy analysis was purchased from Sig-
nalChem (catalog number: H98-63R; lot number: Q356-1). Anti-flag antibody was
purchased from Sigma (catalog number: F1804; lot number: SLBS3530V). Anti-His
antibody was purchased from CusAb (catalog number: CSB-MA000011M0m; lot
number: D0612; clone number: 3G5). Alexa 488-conjucated anti-rabbit (catalog
number: 111-545-003; lot number: 116143) and Cy5-conjugated anti-mouse (cat-
alog number: 115-585-062; lot number: 122994) IgGs were purchased from Jackson
ImmunoResearch Laboratories, Inc. The homemade rabbit anti-KDM8 antibody
was raised against a full length of recombinant KDM8 protein.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The datasets analyzed during the current study are available in The Human Protein Atlas
project (http://www.proteinatlas.org/), OncomineTM (http://www.oncomine.org/), and
The Cancer Genome Atlas (TCGA, http://www.cbioportal.org/) databases. Coordinates
of the PKM2-H391Y and PKM2-R399E structures have been deposited in the RCSB PDB
with ID 4YJ5 and 5X0I, respectively. The plasmids reported in this study have been
submitted to Addgene (deposit number 76407).
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